Search - tctmd.com

Displaying 1 - 20 of 48

Sort: Relevancy | Date

News Daily News

Multiple Antithrombotic Meds Before PCI in NSTE ACS Ups Bleeding Risk, Lowers Survival

Michael O'Riordan

December 13, 2016

News Daily News

With No RCTs, Propensity-Score Matched Analysis Informs Choice Between Cangrelor and GPIs in the Cath Lab

Yael L. Maxwell

December 06, 2016

Presentation TCT 2016

Intravenous P2Y12 Receptor Inhibitors Transitioning to a Potent Oral Anti-platelet Agent if PCI Is Performed Is Optimal Treatment in NSTE-ACS

Presenter: Roxana Mehran, Ferdinando Varbella, Dominick J. Angiolillo

November 01, 2016

Presentation TCT 2016

TCT 6: Simultaneous Impact of Thrombotic and Bleeding Risks on Use of Novel P2Y12 Inhibitors in Contemporary PCI: Results From a Large Single-Center Registry

Presenter: Dimitrios Alexopoulos, Laurent Bonello, Usman Baber

October 31, 2016

Presentation TCT 2016

Transitioning Between Cangrelor and Oral P2Y12 Inhibitors: All the Permutations

Presenter: Deepak L. Bhatt, Christian W. Hamm, Paul A. Gurbel

October 30, 2016

News Daily News

Use of Evidence-Based Medical Therapy Steadily Improving in Acute MI Patients Postdischarge

Michael O'Riordan

September 30, 2016

Presentation ACC 2016

Optimal Loading Dose and Delivery of P2Y12 Inhibitors: Should the Loading Dose Be Crushed?

Presenter: Dominick Angiolillo

April 03, 2016

News Daily News

Calculator Estimates Spontaneous MI Risk in Medically Managed NSTE ACS Patients

Todd Neale

March 16, 2016

Presentation JIM 2016

Oral antiplatelet therapy in elderly New P2Y12 inhibitors are the right choice

Presenter: Alberto Menozzi

February 11, 2016

Presentation JIM 2016

Intravenous P2Y12 Receptor Inhibitors With Powerful Oral Antiplatelets Are The New Best Option!

Presenter: Roxana Mehran

February 11, 2016

News Daily News

Ticagrelor Loading Dose Provides Faster Platelet Inhibition Than Clopidogrel in Ad Hoc PCI

L.A. McKeown

February 09, 2016

News Daily News

Cath-Lab Complications: New Analysis Pinpoints Rate and Risks of Intraprocedural Thrombotic Events in ACS

Shelley Wood

January 21, 2016

News Daily News

Early Data Show Promise for Reversible, Fast-Acting, Antiplatelet Drug PZ-128

Caitlin E. Cox

December 20, 2015

News Daily News

Bivalirudin’s Bleeding Benefits Dampened by PCI Advances, Analysis Shows

Todd Neale

December 14, 2015

News Daily News

Morphine’s Worrisome Effects on Ticagrelor Affirmed in Pharmacokinetic Study

Shelley Wood

October 29, 2015

News Daily News

ADAPT-DES Analysis Reopens Debate Over Possible PPI, Clopidogrel Interaction

Caitlin E. Cox

October 28, 2015

News Conference News TCT 2015

Experts Debate Optimal Pharmacologic Approach for STEMI Patients

October 11, 2015

News Conference News ESC 2015

Prehospital Administration of Ticagrelor Cuts Early Ischemic Events in STEMI Patients

L.A. McKeown

September 01, 2015

News Conference News ESC 2015

CIRCUS: Transplant Rejection Drug Fails to Reduce Infarct Size in Anterior STEMI

L.A. McKeown

August 30, 2015

News Daily News

Cardiac Rehab After Acute MI Linked to Improved Survival, Medication Adherence

Leah Lawrence

August 30, 2015

Advertisement

Multiple Antithrombotic Meds Before PCI in NSTE ACS Ups Bleeding Risk, Lowers Survival

With No RCTs, Propensity-Score Matched Analysis Informs Choice Between Cangrelor and GPIs in the Cath Lab

Intravenous P2Y12 Receptor Inhibitors Transitioning to a Potent Oral Anti-platelet Agent if PCI Is Performed Is Optimal Treatment in NSTE-ACS

TCT 6: Simultaneous Impact of Thrombotic and Bleeding Risks on Use of Novel P2Y12 Inhibitors in Contemporary PCI: Results From a Large Single-Center Registry

Transitioning Between Cangrelor and Oral P2Y12 Inhibitors: All the Permutations

Use of Evidence-Based Medical Therapy Steadily Improving in Acute MI Patients Postdischarge

Optimal Loading Dose and Delivery of P2Y12 Inhibitors: Should the Loading Dose Be Crushed?

Calculator Estimates Spontaneous MI Risk in Medically Managed NSTE ACS Patients

Oral antiplatelet therapy in elderly New P2Y12 inhibitors are the right choice

Intravenous P2Y12 Receptor Inhibitors With Powerful Oral Antiplatelets Are The New Best Option!

Ticagrelor Loading Dose Provides Faster Platelet Inhibition Than Clopidogrel in Ad Hoc PCI

Cath-Lab Complications: New Analysis Pinpoints Rate and Risks of Intraprocedural Thrombotic Events in ACS

Early Data Show Promise for Reversible, Fast-Acting, Antiplatelet Drug PZ-128

Bivalirudin’s Bleeding Benefits Dampened by PCI Advances, Analysis Shows

Morphine’s Worrisome Effects on Ticagrelor Affirmed in Pharmacokinetic Study

ADAPT-DES Analysis Reopens Debate Over Possible PPI, Clopidogrel Interaction

Experts Debate Optimal Pharmacologic Approach for STEMI Patients

Prehospital Administration of Ticagrelor Cuts Early Ischemic Events in STEMI Patients

CIRCUS: Transplant Rejection Drug Fails to Reduce Infarct Size in Anterior STEMI

Cardiac Rehab After Acute MI Linked to Improved Survival, Medication Adherence

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content